Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Dreyling

Showing results (81-90 of 336) with videos related to

Pageof 34
Sort By:
Deutsches Arzteblatt International|July 13, 2018
The Diagnosis and Treatment of Primary CNS LymphomaLouisa von Baumgarten, Gerald Illerhaus, Agnieszka Korfel, et al.
Clinical Lymphoma & Myeloma|May 2, 2009
Biomarkers and prognosis in malignant lymphomasAnton Hagenbeek, Randy D Gascoyne, Martin Dreyling, et al.
Haematologica|June 1, 2005
Microsatellite instability and p53 mutations are characteristic of subgroups of acute myeloid leukemia but independent eventsGerhard Herzog, Juxian Lu-Hesselmann, Yvonne Zimmermann, et al.
The Cochrane Database of Systematic Reviews|September 14, 2012
Bendamustine for patients with indolent B cell lymphoid malignancies including chronic lymphocytic leukaemiaLiat Vidal, Anat Gafter-Gvili, Ronit Gurion, et al.
Histopathology|March 16, 2011
Follicular dendritic cells in follicular lymphoma and types of non-Hodgkin lymphoma show reduced expression of CD23, CD35 and CD54 but no association with clinical outcomeMi Kyung Jin, Eva Hoster, Martin Dreyling, et al.
Leukemia & Lymphoma|August 4, 2015
Temsirolimus inhibits cell growth in combination with inhibitors of the B-cell receptor pathwayAnna-Katharina Zoellner, Stephan Bayerl, Grit Hutter, et al.
European Journal of Haematology|April 5, 2018
Transient antagonism of anti-CD20 monoclonal antibodies and PI3K inhibitor idelalisib in DLBCL cell linesAnna-Katharina Zoellner, Nico Peter, Yvonne Zimmermann, et al.
Leukemia & Lymphoma|February 1, 2017
Recent advances and future directions in mantle cell lymphoma research: report of the 2016 mantle cell lymphoma consortium workshopBrad S Kahl, Martin Dreyling, Leo I Gordon, et al.
Leukemia & Lymphoma|March 11, 2015
Everolimus maintenance in patients with mantle cell lymphoma not eligible for intensive therapy: results of a prematurely closed phase 2 studySusanne Schreiber, Alexander Hoellein, Thomas Decker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 22, 2004
Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study GroupGeorg Lenz, Martin Dreyling, Eva Schiegnitz, et al.
Pageof 34

Showing results (81-90 of 336) with videos related to

Sort By:
Pageof 34
Deutsches Arzteblatt International|July 13, 2018
The Diagnosis and Treatment of Primary CNS LymphomaLouisa von Baumgarten, Gerald Illerhaus, Agnieszka Korfel, et al.
Clinical Lymphoma & Myeloma|May 2, 2009
Biomarkers and prognosis in malignant lymphomasAnton Hagenbeek, Randy D Gascoyne, Martin Dreyling, et al.
Haematologica|June 1, 2005
Microsatellite instability and p53 mutations are characteristic of subgroups of acute myeloid leukemia but independent eventsGerhard Herzog, Juxian Lu-Hesselmann, Yvonne Zimmermann, et al.
The Cochrane Database of Systematic Reviews|September 14, 2012
Bendamustine for patients with indolent B cell lymphoid malignancies including chronic lymphocytic leukaemiaLiat Vidal, Anat Gafter-Gvili, Ronit Gurion, et al.
Histopathology|March 16, 2011
Follicular dendritic cells in follicular lymphoma and types of non-Hodgkin lymphoma show reduced expression of CD23, CD35 and CD54 but no association with clinical outcomeMi Kyung Jin, Eva Hoster, Martin Dreyling, et al.
Leukemia & Lymphoma|August 4, 2015
Temsirolimus inhibits cell growth in combination with inhibitors of the B-cell receptor pathwayAnna-Katharina Zoellner, Stephan Bayerl, Grit Hutter, et al.
European Journal of Haematology|April 5, 2018
Transient antagonism of anti-CD20 monoclonal antibodies and PI3K inhibitor idelalisib in DLBCL cell linesAnna-Katharina Zoellner, Nico Peter, Yvonne Zimmermann, et al.
Leukemia & Lymphoma|February 1, 2017
Recent advances and future directions in mantle cell lymphoma research: report of the 2016 mantle cell lymphoma consortium workshopBrad S Kahl, Martin Dreyling, Leo I Gordon, et al.
Leukemia & Lymphoma|March 11, 2015
Everolimus maintenance in patients with mantle cell lymphoma not eligible for intensive therapy: results of a prematurely closed phase 2 studySusanne Schreiber, Alexander Hoellein, Thomas Decker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 22, 2004
Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study GroupGeorg Lenz, Martin Dreyling, Eva Schiegnitz, et al.
Pageof 34